A study out of Japan says that women who get "dose-dense" chemotherapy - which means Taxol (my flower power drug) divided into equal doses each Monday while getting carboplatin only on the first Monday of each cycle - have an approximately 2 year survival advantage on average over women who get all carboplatin and taxol only on the first monday of each cycle.
I am getting dose dense chemotherapy - so this is good news. Add that to the avastin advantage and i am feeling very good about having decided to enter this clinical trial.
Also getting rather tired of constant and growing fatigue and being confined and being bald. ONLY 5 more weeks to go!